publication date: May. 12, 2017

Conversation with The Cancer Letter

Niederhuber on Trump’s budget blueprint: “We should not panic yet”

John Niederhuber

Former NCI director,

Executive vice president & CEO,
Inova Translational Medicine Institute



Former NCI director John Niederhuber is keeping relatively calm about the White House plan to slash the NIH budget.

“I guess my reaction was that, this is the White House recommendation, the President’s recommendation,” said Niederhuber, who served as NCI director from 2006 to 2010. “When people have asked me about it, I’ve said we should not panic yet. This is a process and that’s the beginning of the process.”

The process—and, to some, the panic—began on March 16, when President Trump published a “blueprint” version of his budget that calls for an 18.3 percent cut to the biomedical enterprise in the US (The Cancer Letter, March 17).

Though he remains hopeful, Niederhuber, executive vice president and CEO of the Inova Translational Medicine Institute, said he has difficulty imagining the impact of the cut the White House has proposed.

“I believe it would be… I hate to use the word ‘devastating,’ but I think that kind of cut would be very, very difficult for us in managing our day-to-day operations,” Niederhuber said. “Our research universities would have tremendous difficulty managing such a deep cut in revenue for a variety of reasons.

Continue reading Niederhuber on Trump’s budget blueprint: “We should not panic yet”

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.